Limfadenopati Tuberkulosis dengan Drugs-induced Hepatitis (DIH) di Sikka, Nusa Tenggara Timur, Indonesia
DOI:
https://doi.org/10.55175/cdk.v51i1.1181Keywords:
Drugs-induced hepatitis, lymphadenitis TB, OATAbstract
Background: The most common extrapulmonary TB is lymph node TB in 35% cases of worldwide. Drug-induced hepatitis (DIH) is the possible adverse effect of antimycobacterial agents. Case: An 18-year-old male with multiple tender lumps on the right side of his neck for the last 2 weeks. Physical findings were multiple masses in the right anterior supraclavicular and submandibular region. Biopsy revealed suppurative granulomatous lymphadenitis. The diagnosis is TB lymphadenitis and the first regimen of anti-TB was given, but the patient developed nausea and vomiting and increased AST/ALT after 5 days. Anti-TB was temporarily discontinued. Anti-TB regimen was resumed after clinical and laboratory returned to normal. Conclusion: Patients with TB and DIH need to be treated individually depending on their tolerance to the drugs. Careful clinical and laboratory monitoring was needed to prevent adverse effects and for best results.
Downloads
References
Jameson J, Kasper D, Longo D, Fauci A, Hauser S, Loscalzo J. Harrison's principles of internal medicine. 20th ed. New York: Mc Graw Hill Education; 2018.
Subuh M, Priohutomo S, Dinihari T, Siagian V, Uyainah A, Nawas A, et al. Pedoman nasional pengendalian tuberkulosis. Jakarta: Kementerian Kesehatan RI; 2014.
Kementerian Kesehatan. Peraturan Menteri Kesehatan Republik Indonesia nomor 67 Tahun 2016. Jakarta; 2016.
Menteri Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor.HK.01.07/Menkes/755/2019 tentang pedoman nasional pelayanan kedokteran tata laksana tuberkulosis. Jakarta; 2019.
Pang Y, An J, Shu W, Huo F, Chu N, Gao M, et al. Epidemiology of extrapulmonary tuberculosis among inpatients, China, 2008–2017. Emerging Infect Dis. 2019;25(3):457-64.
Wesnawa M, Kusmiati T. Drug induced hepatitis pada tuberkulosis paru dengan multisite tuberkulosis ekstraparu. J Respirasi. 2020;5(2):34.
Saukkonen J, Cohn D, Jasmer R, Schenker S, Jereb J, Nolan C, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Critical Care Med. 2006;174(8):935-52.
Sun Q, Zhang Q, Gu J, Sun W, Wang P, Bai C, et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous druginduced liver injury: A prospective cohort study. Pharmacoepidemiol Drug Safety 2016;25(8):908-17.
Bulut Gökten D, Katipoglu B, Basara E, Ates I, Yılmaz N. A case report of peritoneal tuberculosis: A challenging diagnosis. Case Rep Infect Dis. 2018;2018:1-3.
Treatment of tuberculosis: Guidelines. 4th ed. WHO Press; 2020.
Latief M, Dar W, Sofi N, Dar I, Kasana B, Hussain M, et al. Novel risk factors and early detection of anti tubercular treatment induced liver injury-Looking beyond American Thoracic Society guidelines. Indian J Tuberculosis 2017;64(1):26-32.
Mohan N, Kumar J, Chakrawarty A, Ranjan P. Comprehensive review of anti-tubercular treatment induced liver injury. Internat J Basic Clin Pharmacol. 2015;4(3):397-403.
Kimura Y, Shimada M, Kawashima M, Yamane A, Nagai H, Matsui H. Relapse of cervical tuberculous lymphadenitis immediately after completion of effective antituberculosis treatments. Respirol Case Reports 2020;8(4):e00555.
Jiao Y, Chen J, Zeng X. Acute paradoxical reaction of cervical tuberculous lymphadenitis prompted by a misuse of etimicin sulphate. BMJ Case Rep. 2012;2012:bcr1220115458.
Seok H, Jeon J, Oh K, Choi H, Choi W, Lee Y, et al. Characteristics of residual lymph nodes after six months of antituberculous therapy in HIVnegative individuals with cervical tuberculous lymphadenitis. BMC Infect Dis. 2019;19(1):867.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 David Denada Rahmad, Asep Purnama
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
